Login to Your Account



Ribozyme Financing Gets $48M; Focus Shifts To RNAi Research

By Randall Osborne


Thursday, February 13, 2003
With its shares trading at under a half dollar, Ribozyme Pharmaceuticals Inc. pulled off an agreement for $48 million in financing, the keystone in a deal that gives investors control of the company and changes its direction to focus on RNA interference. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription